Articles from CinRx Pharma

CinRx Pharma, a multi-asset clinical development organization, today announced the appointment of Rez Halse, PhD, as President. Dr. Halse brings more than 25 years of leadership in the pharmaceutical and biotech sectors, specializing in therapeutic discovery, translational development, business development, licensing, and venture capital.

CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced that it has completed enrollment in the envision3D Phase 2 clinical trial of deudomperidone in adults with diabetic gastroparesis, with topline safety and efficacy results anticipated in Q1 2026.

CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, today announced the initiation of the Phase 1 MAD clinical trial for CIN-110, a novel, highly selective PYY3-36 analog for the treatment of obesity. This Phase 1 MAD clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 in adults with obesity. The initiation of this MAD trial follows the ongoing SAD study, where CIN-110 was well-tolerated with noteworthy reductions in caloric intake and body weight. The SAD study will be used to inform dosing decisions in the current MAD study.

CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million. Participants in the round include prior investors comprised of industry insiders and high-net-worth individuals. To date, CinRx has launched five companies (“CinCos”) focused primarily on cardiovascular, metabolic and gastrointestinal conditions. In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies. CinRx plans to use the funds to advance development of its existing portfolio programs and assets to expand in key areas of high unmet medical need.

CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline. The members of CinFina’s SAB include renowned metabolic and obesity academic researchers and expert clinicians.

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis.

CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6th – 9th in Chicago, Illinois. The poster, titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study In Healthy Subjects” will highlight data on the promise of deudomperidone for the long-term management of gastroparesis.

CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis. Deudomperidone is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being evaluated for the chronic treatment of patients who currently have no therapeutic options for long term management. Gastroparesis is a syndrome defined by delayed gastric emptying in the absence of any physical obstruction and symptoms include bloating, nausea, vomiting, postprandial fullness, and early satiety.

CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today that Gavin Samuels, M.D., M.B.A has assumed the role of Chief Business Officer. In his new role, Gavin will be responsible for leading corporate, strategic and business development and transactions for the CinRx portfolio.

CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109. CIN-109 is a novel, long-acting first-in-class growth differentiation factor 15 (GDF-15) analog being developed as a treatment for obesity. CinFina is a subsidiary ‘CinCo’ of CinRx dedicated to developing four novel, first-in-class therapies for obesity and weight loss and its associated co-morbidities. CIN-109 is the first to advance into Phase 1.